1Sem.ยท

๐Œ๐จ๐๐ž๐ซ๐ง๐š: ๐๐Ÿ‘ ๐‘๐ž๐ฏ๐ž๐ง๐ฎ๐ž ๐’๐ฎ๐ซ๐ ๐ž๐ฌ ๐Ÿ๐Ÿ—%, ๐‘๐ž๐ญ๐ฎ๐ซ๐ง๐ฌ ๐ญ๐จ ๐๐ซ๐จ๐Ÿ๐ข๐ญ๐š๐›๐ข๐ฅ๐ข๐ญ๐ฒ, ๐‘๐š๐ข๐ฌ๐ž๐ฌ ๐…๐˜๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” ๐†๐ฎ๐ข๐๐š

$MRNA (-3,96ย %)


๐Ÿ“Š ๐‘๐ž๐ฌ๐ฎ๐ฅ๐ญ๐ฌ

โ€ข GAAP EPS: $0.38 (Normalized Est. -$1.35, not directly comparable), vs. -$0.51 YoY.

โ€ข Revenue: $1.313B (Est. $890.22M) โœ…, +29% YoY.

โ€ข Net Income: $162M (vs. -$200M YoY).

โ€ข U.S. Revenue: $780M.

โ€ข International Revenue: $533M.

โ€ข R&D Expenses: $583M, -27% YoY.

โ€ข Cost of Sales: $318M, +54% YoY.

โ€ข Cash & Investments: $8.0B.

โ €

๐ŸŽฏ ๐†๐ฎ๐ข๐๐š๐ง๐œ๐ž

โ€ข FY2026 Revenue Growth: +15%โ€“25%, raised from up to +10%.

โ€ข FY2026 R&D Expenses: ~$2.7B, reduced from ~$2.9B.

โ€ข FY2026 SG&A Expenses: ~$1.0B, unchanged.

โ€ข FY2026 Capital Expenditures: ~$200M.

โ€ข FY2026 Year-End Cash & Investments: $8.1Bโ€“$8.3B, raised from $4.7Bโ€“$5.2B.

โ €

๐Ÿ“Œ ๐Š๐ž๐ฒ ๐“๐š๐ค๐ž๐š๐ฐ๐š๐ฒ๐ฌ

โ€ข Q3 revenue beat consensus by ~47.5%, driven primarily by stronger international COVID vaccine sales.

โ€ข Returned to GAAP profitability with $162M in net income, a $362M improvement YoY.

โ€ข Phase 3 intismeran + KEYTRUDA reduced melanoma recurrence or death risk by 42% versus KEYTRUDA alone.

โ€ข Distant metastasis or death risk declined 38% in the same Phase 3 trial.

โ€ข Received U.S. approval for mFLUSIVA influenza vaccine, its fifth approved product globally.

โ€ข Flu/COVID combination vaccine received approval in Canada following earlier EU authorization.

โ€ข Norovirus Phase 3 interim analysis failed to meet early-success criteria; no additional cohort planned this season.

โ€ข Reduced FY2026 R&D spending outlook by $200M amid continued cost discipline.

โ€ข Completed ~$3B convertible notes financing, generating ~$2.6B in net proceeds.

โ€ข Cash position increased to $8B, supported by debt financing despite a $950M litigation settlement payment and operating cash usage.

โ€ข Pivotal propionic acidemia trial data expected in 2026.

โ€ข Moderna Analyst Day scheduled for November 12.

โ €

๐Ÿ’ฌ ๐Œ๐š๐ง๐š๐ ๐ž๐ฆ๐ž๐ง๐ญ ๐‚๐จ๐ฆ๐ฆ๐ž๐ง๐ญ๐š๐ซ๐ฒ

โ€œWe delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.โ€

4
Participez ร  la conversation